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ABSTRACT 
A PHASE II TWO STAGE CLINICAL TRIAL DESIGN TO HANDLE LATENT 
HETEROGENEITY FOR A BINARY RESPONSE 
Christopher N. Barnes 
April 15,2010 
Phase II clinical trial are generally single arm trial where a homogeneity 
assumption is placed on the response. In practice, this assumption may be violated 
resulting in a heterogeneous response. This heterogeneous or overdispersed response can 
be decomposed into distinct subgroups based on the etiology of the heterogeneity. A 
general classification model is developed to quantify the heterogeneity. The most 
common Phase II trial design used in practice is the Simon 2-stage design which relies on 
the assumption of response homogeneity. This design is shown to be flawed under the 
assumption of heterogeneity with errors exceeding the target trial errors. To correct for 
the error inflation, a modification is made to the Simon design if heterogeneity is detected 
after the first stage trial conduct. The trial sample size is increased using an empirical 
estimate for the variance inflation factor and the trial is then completed with design 
parameters constructed through the posterior predictive Beta-binomial distribution given 
the first stage results. The new design, denoted the 2-stage Heterogeneity Adaptive 
(2HA) design, is applied to a two subgroup problem under latent heterogeneity. Latent 
heterogeneity represents the most general form of heterogeneity, no information is known 
prior to trial conduct. The results, through simulation, show that the target errors can be 
v 
maintained with this modification to the Simon design under a wide range of 
heterogeneity. 
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The primary assumption for most Phase II single arm binary trials is the 
assumption of response homogeneity. Response homogeneity is defined as the variance 
of the response being bounded by the variance of a binomial distribution given a response 
rate, Jr (Simon 1989). Many single arm Phase II trials do not adhere to this assumption 
in practice. When the variance of the response, denoted x which corresponds to the 
number of patients with a positive response, exceeds the binomial variance, 
v ( x) > nJr ( 1 - Jr) , 
the response is deemed a heterogeneous response (Williams 1982; Yamamoto and 
Yanagimoto 1994; Collet 2003). The common structure of this heterogeneous response 
is a response profile of disjoint subgroups, 1t = ( Jr1, Jr2 , ••• , Jrg ) , for i = 1,2, ... , g 
subgroups where Jri is the response probability for the ith subgroup and there exists at 
least two distinct subgroup response rates, Jri *- Jri , for some i *- i'. In contrast, the 
response in a homogeneous population follows a single response rate, where Jr = Jri = Jri , 
for all i *- i'. Subgroup membership is defined by a single or multiple set of markers 
(London and Chang 2005; Thall and Wathen 2008; Behrendt and Gehan 2009). The 




or prognostic markers such as baseline insulin levels or single/multiple genomic markers 
such as the BRCAI gene in Breast cancer. 
A common practice in clinical trials when heterogeneity is assumed and the 
markers are known is to use a simple or weighted mean of the response profile of the 
subgroups to compute a single response rate which adheres to the homogeneity 
assumption (Green 1982; Gadbury and Iyer 2000; Emerson, Kittelson et al. 2007; 
Emerson, Kittelson et al. 2007; Ayanlowo and Redden 2008; Thall and Wathen 2008; 
Tuma 2008; Wathen, Thall et al. 2008). The weights are derived from either the known 
population proportions of each subgroup or estimated from a random sample of patients. 
This leads to one of two averaging constraints on the response profile. Let Jrr for 
T = {O, I} , the null response rate and alternative response rate respectively, be the 
response rate, then the average constraints are defined as 
or 
I WiJrr; = Jrr 
i=1 
for simple average and g subgroups and for a weighted average, where Wi = nj / n is the 
weight for subgroup i, nj is the number of patients in subgroup i for a total of 
g 





Using methods that rely on the homogeneity assumption when heterogeneity is 
true will lead to biased inferences (Russek-Cohen and Simon 1997), incorrect early 
stopping of the trial (Thall, Wathen et al. 2003; Thall and Wathen 2008; Wathen, Thall et 
al. 2008) or a subsequent failure of the Phase III trial resulting in a substantial loss of 
resources (Rosner, Stadler et al. 2002; Stadler 2007; Tuma 2008). This is primarily due 
to the departure of the trial data distribution from the model distribution from which the 
trial parameters are constructed, the binomial distribution. It will be shown that this 
approach, when applied to the most common Phase II trial design, the Simon 2-stage 
trial, will result in unbounded errors, false positive or false negative trial conclusions, 
dependent on a combination of the magnitude of difference between the subgroup 
responses and the difference in subgroup weights. 
A second method when heterogeneity is present is to conduct multiple trials, one 
for each subgroup. This will result in a heavy strain on trial resources especially for early 
development Phase II trials. Due to possible low patient accrual in one or more trials, 
trials may not be completed; losing valuable information on the treatment effect over the 
entire population. Conducting multiple trials ignores a fundamental assumption of the 
motivation for a single trial; all patients share a common disease state. It is assumed that 
the response rate in one subgroup will be partially correlated with the response rate in the 
other subgroups. Secondly, the subgroups must be known in advance of the trial conduct 
to conduct multiple trials which is not always a practical situation. 
In the last few years, multiple methods have been developed to account for 
response heterogeneity by quantifying the structure of the subgroups in the test statistic 
3 
(London and Chang 2005; Thall and Wathen 2008). Two examples are briet1y 
mentioned. The simplest form, the unconditional stratified test, assumes a stratified 
response based on known subgroups and modifies the Binomial test statistic into the form 
of a stratified log-rank test (London and Chang 2005). The resulting test has a global 
hypothesis, either the compound/treatment provides efficacy evidence to move onto 
further targeted Phase II testing or Phase III testing or it does not. 
Bayesian methods have also been developed which rely on hierarchical models or 
ANCOVA models to model the structure of the subgroups (Thall, Wathen et al. 2003; 
Wathen, Thall et al. 2008). The Bayesian methods employ the desirable characteristic of 
local hypothesis tests, rejection of the efficacy hypothesis on a subgroup level allowing 
some subgroups to succeed while others may fail. Secondly, the Bayesian methods 
minimize the overall sample size as compared to running multiple trials by sharing 
response information across the subgroups when making decisions on individual 
subgroups. Drawbacks are that Bayesian methods will use considerably more 
computational resources and do not rely on fixed sample size estimates. The limiting 
drawback to implementing these designs in actual trial conduct and the remaining 
methods described in the literature is that all the methods rely on the assumption that the 
composition of the subgroups is known prior to trial conduct. The methods provide no 
methodology for when the subgroups are latent prior to trial conduct. 
Recently, there has been a shift in focus to randomized Phase II designs to help 
mitigate heterogeneity in the response (Lee and Feng 2005). Randomized trials can 
provide a mechanism to estimate the source of the heterogeneity and the type of 
4 
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heterogeneity. A major drawback to the randomized designs is the substantial increase in 
trial resources, usually a doubling of trial resources to reject a global hypothesis. The use 
of a randomized design is not always practical at such an early stage of estimating 
treatment efficacy due to patient accmal issues and will not be considered in this paper. 
In practice, the composition of the subgroups is not known or only partially 
hypothesized. Latent subgroups are a more common problem in clinical trials and may 
provide an etiology for the high failure rate of Phase II trials. Phase II trials are not 
conducted unless there is substantial ex vivo evidence of compound/treatment efficacy. 
In practice, many Phase II trials still fail when this evidence is present; presenting the 
issue of whether the trial failure rests on inadequate efficacy of the compound/treatment, 
inadequacy of the trial design, or inaccurate estimates of the hypothesized response. We 
focus on the second issue, inadequacy of the trial design as a possible solution to the high 
failure rate of Phase II trials. 
Before developing a new trial design, the stmcture to heterogeneity must be 
quantified. We have developed a classification model to quantify response heterogeneity, 
through the subgroups, into three classes, historical response heterogeneity (HRH), 
assumed response heterogeneity (ARH) and general response heterogeneity (GRH). 
These classes can help to detect when a trial may fail due to heterogeneity. 
HRH is composed of known subgroups. In simplest terms, the subgroups are 
known either from responses to similar treatments, known biological motivations or can 
be estimated from the response in the control group of a randomized trial design denoted 
as the null response. Under HRH, the null response, e.g. response under no treatment, is 
5 
heterogeneous and the treatment effect is homogenous resulting in a heterogeneous 
response structured by the heterogeneity of the null hypothesis response. 
In contrast, ARH assumes a homogeneous null response and a heterogeneous 
treatment effect. Under ARH, no known or latent subgroups exist on prior treatment, but 
a Treatment x Marker effect is identified causing the treatment and thus response under 
the treatment, denoted the alternative response, to vary by this Treatment x Marker 
subgroup composition. In both the previous classes, the alternative responses are unique. 
Each disjoint subgroup can be identified from a unique alternative treatment response 
rate. 
A generalization of the first two classes is general response heterogeneity. GRH 
is composed of possibly both heterogeneous historical response and heterogeneous 
treatment effects. GRH does not always result in uniquely identifiable subgroups through 
the alternative response, but results in unique subgroups through the source of the 
heterogeneity. Multiple different combinations of null response and treatment effect can 
result in the same alternative response. 
Under the context of a single stage design, in order to determine the composition 
of subgroups, a pre-clinical analysis would have to be conducted on a set of patients 
which would entail exposing the patients to the compound/treatment to determine 
response. A second set of patients would be used in the resulting trial. This is not an 
optimal use of trial resources. The first set of patients, in effect, can be construed as a 
separate trial in which the data is thrown away; not providing response information for 
use in the actual trial. A more suitable solution would be to conduct the "pre-clinical" 
6 
analysis during the trial; hence, minimizing time and patient resources. No information 
would be lost, all patients that undergo treatment would used in estimating response. The 
two stage designs of Simon provide a natural break for this analysis, between stages. 
While the two stage process is a suitable solution to this problem and comprises the 
majority of all conducted Phase II trials, the use of the binomial distribution as the model 
distribution is not appropriate. 
We develop a two stage design which begins as the popular Simon 2-stage design 
and is adapted to accommodate heterogeneity if heterogeneity is identified between the 
conduct of the two stages. If no source of heterogeneity is identifiable, the trial continues 
on under the Simon design; otherwise an adaption is made and the trial is evaluated using 
new adaptive trial parameters. 
The paper is organized as follows. Chapter two introduces the basic two stage 
design of Simon, the heterogeneity model and trial error construction. Chapter three 
provides a literature review of the current methods to handle heterogeneity with non-
latent heterogeneity. Chapter four introduces the main components of the new trial 
design, subgroup identification, heterogeneity tests, the trial's model distribution, and 
finally, the trial algorithm. Chapter five investigates the operating characteristics of the 
Simon design and new trial design under heterogeneity with concluding remarks and 
future direction in Chapter six. 
7 
CHAPTER 2 
SIMON DESIGN, HETEROGENEITY MODEL AND ERRORS 
2.1 Simon Phase II Designs 
The basic two stage binary Phase II trial design was first implemented by Gehan 
(Gehan 1961). Shultz modified the Gehan design to require a minimum of at least one 
response in the first stage with equal size sample sizes in both stages (Schultz, Nichol et 
al. 1973). The Gehan design can allow no response in the first stage. Simon later 
popularized the Shultz design by allowing unequal size sample sizes in the stages and 
constructing a search algorithm to determine the optimal and minimax designs which 
meet a set of sample size optimization criteria (Simon 1989). 
For simplicity, the term treatment denotes a compound, treatment or regimen. Let 
x be the realized data in stage one with (lj, n)) as the critical value and sample size for 
stage one, and y be the realized data in stage two with (r, n) as the critical value and 
sample size for stage one and two combined. The trial parameters, (lj, nl' r, n) , are 
constructed to estimate if the trial response rate under treatment, 1[, is greater than or 
equal to a clinically relevant target response rate, denoted the alternative response, 
1[) = 1[0 + t5 where 1[0 is the null response under no treatment and t5 is the treatment effect, 
or formally, Ho: 1[ < 1[) vs. H) : 1[ ~ 1[), the null and alternative hypothesis respectively. 
8 
If the sum of responses for the treatment in the first stage is not larger than the 
stage one critical value, x:::; fj , the trial is stopped for futility; otherwise, the trial 
proceeds to stage two enrolling an additional n - n l patients. Once all of the patients 
have been evaluated, the sum of responses over both stages is compared to a second 
critical value. If the sum of responses is not larger than the stage one + stage two 
combined critical value, x + y :::; r , then the treatment is estimated to not have the desired 
effect; otherwise, the novel treatment is estimated to be promising with a response rate of 
The construction of the parameters of the trial, (fj, n], r, n) , is dependent on the 
target errors of the trial known as the type I error or size of the trial, a, and type II error 
or I-power of the trial, f3. As such, the power of the trial is 1 - f3. The critical values 
and sample sizes for each stage are chosen from a set of possible designs constrained to 
satisfy the type I and type II errors per 
rnin( n[ ,r) 
P (reject Hoi Jr = JrT ) = Bin (fj I n" JrT ) + I bin (x I nl' JrT ) Bin (r - x I nl' JrT ) (4) 
r:::::'l+! 
where bin is the binomial probability mass distribution and Bin is the binomial 
cumulative distribution for treatments T = {O, I} , the null and alternative hypothesis or 
null and alternative response rate, respectively. 
In practice to determine the parameters, n], n, fj, r , a sample size for stage I is first 
chosen such that P(reject Ho I TC = TCO,N] =n l ) E (.50, .80), also known as the probability of 
9 
early termination (PET). Using an iterative algorithm, given (n1' fj) , a total sample size is 
selected to satisfy (4) under the pre-specified target type I and type II errors. This 
process is repeated to find a set number, say 50, solutions that satisfy the error 
constraints. Two of the solutions are then selected as the minimax and optimal designs. 
The optimal design is the design that minimizes the expected sample size, 
EN(Ho) = n1 + (1- PET) ( n -11,), 
under the null hypothesis over all possible designs and the minimax design is the design 
that minimizes EN over all designs with the minimum total sample size, n. 
Under a Simon design with no heterogeneity, no type I error is spent in the first 
stage. This is due to the single bound of the critical value. The bound is for futility only. 
Onl y a percentage of power is spent in the first stage. This is evidenced in the form of (4) 
where the second component on the right hand side is a weighted sum weighted by the 
"power" spent in the first stage. Most Phase II designs follow this approach, only a 
futility bound in the earlier stages, since the primary goal of a Phase II trial is to estimate 
if the treatment is promising for further testing, not to establish is the treatment is 
efficacious. 
2.2 A Model for heterogeneity 
Response heterogeneity in a population can be modeled by deconstructing the 
response rate into subgroups to form a response profile, 1T = (lZ'1' lZ'2'"'' lZ'g) ,composed of 
g subgroups where lZ'i is the response rate for the ith subgroup and there exists lZ'i f:. lZ'i' 
10 
(5) 
for some i -:j:. i'; in contrast, iC; = iC;' for all i -:j:. i' in a homogeneous population. The 
resulting subgroup model provides the basic platform to compare methodology for 
heterogeneous responses. 
Let 11'T = ( iCT I' iCr 2'· •• , TCT g ) be the vector of subgroup responses for 
i = 1,2, ... , g subgroups where iCT ; is the response rate in subgroup i for treatment 
T = {O, I}. T = 0 denotes the known standardlhistorical treatment response, e.g. the null 
response, and T = I denotes the hypothesized experimental treatment response, e.g. the 
alternative response. 
In addition, let the baseline historical response rate for the historical response 
profile be denoted by iC~ = arg min (iCo; ) . Furthermore, let TJ; be the prognostic response 
g 
heterogeneity between subgroup i and the baseline historical response, I; be the 
predictive heterogeneity in treatment effect over the baseline treatment effect, 
5* = arg min ( 5..;) where 5..; are the treatment effects for each subgroup, such that, 
where 0 ~ iCT ; ~ 1 ,defines a subgroup mixture model for heterogeneity (Barnes and Rai 
2010). 10 is a membership indicator. 
The historical response heterogeneity, TJ;, is a fixed prognostic effect while the 




classification of response heterogeneity rests on the structure of the historical response 
profile and the treatment effect profile. To quantify the range of response heterogeneity, 
three classes, historical response heterogeneity (HRH), assumed response heterogeneity 
(ARH), and general response heterogeneity (GRH), are constructed. For all i"# iI, 
defines the HRH class and 
defines the ARH class. In both classes, the experimental treatment response rates are 
umque. 
The third class, GRH, relaxes the unique response constraint. A mixture of prognostic 
and predictive heterogeneity can result in non-unique experimental responses. The 
etiology of each subgroup's heterogeneity is the basis for the subgroup construction and 
is assumed to be unique. GRH is defined as follows. There exists some i"# i I for which 
In equation (7), a known covariate exists for which a prior historical response profile 
can be constructed. The prior distribution of historical response rates, given the historical 
covariate, is hypothesized to be consistent in the current trial. Heterogeneity in the 
experimental response profile is attributed to the different known historical response 
rates, !COi "# !COi" The treatment effects are homogeneous across the subgroups, ~ = ~, . 




heterogeneous treatment effects, ~ 1:- ~ , where the estimated historical response rates are 
homogeneous, 1[Oi = 1[Oi'. The heterogeneity is measured by the inequality of the 
treatment effects between subgroups due to a covariate-treatment interaction as opposed 
to the inequality of historical rates as in (7). 
The general form of response heterogeneity, GRH, is a composite of both of the 
previous classes of response heterogeneity. The general form (9) occurs when both the 
historical response rates and treatment effects are hypothesized to be heterogeneous. For 
example, under a three subgroup model, historically gender, (M, F), leads to different 
historical response rates, 1[01 = 1[02 = 1[OM ' and 1[03 = 1[OF where 1[OM 1:- 1[OF. A biomarker 
present in males is hypothesized to lead to a further differentiation of response rates, male 
biomarker present and male biomarker absent, resulting in the following three possible 
response models, 
{
1[1I 1:- 1[12 1:- 1[13 
1[01 = 1[02 1:- 1[03 and 1[11: 1[12 = 1[13 
1[11 -1[12 1:- 1[13 
The prognostic heterogeneity differs between gender, 171 = 172 1:-173 , with a predictive 
heterogeneity only affecting the males, 'I 1:- '2 and '3 = o. The first possible 
experimental response model results in three unique response rates. While the remaining 
two models result in two unique response rates with the effect of the male biomarker, 
present or absent, providing the same experimental response rate as for females. When 
no information is known about the structure of the heterogeneity, it is appropriate to 
13 
(10) 
assume a general class stmcture. For this reason, the focus, in evaluating a new trial 
design under latent heterogeneity, will rest on the GRH class of heterogeneity. 
2.3 Heterogeneity model example 
To illustrate the different classes of heterogeneity, the following hypothetical 
example is provided. A trial is conducted to determine the response rate of dmg A to 
treat early to moderate stage colon cancer, stage I-III. The researchers wish to test 
Ho : Ir = Iro =.3 against HI : Ir >.3 with a target treatment effect of 5 =.2 resulting in 
the alternative response of Irl =.5. Table lea-d) provides four possible scenarios under a 
g = 3 subgroup trial for different groups of researchers testing the same dmg. For 
simplicity, the sample sizes of the subgroups are assumed to be equal. 
The first scenario, table 1 a, is an example of HRH. Research group I knows that 
historically Dmg A leads to a response profile based on cancer stage for a similar 
disease, breast cancer. This prognostic difference is assumed to be consistent in the 
current trial due to the similarity of pathways being targeted between the two cancers. 
The historical response profile for the standard treatment is 
Teo = (lrOI ' Ir02 ' Ir03) = (.4, .3,.2) with lio =.3 constmcted from a baseline historical 
response rate of Ir~ =.2 and a historical heterogeneity effect of 11 = (771,772,773 ) = (.2, .1, 0). 
The objective is to test for a common treatment effect, () = ( ~ , 52 ,63 ) = (.2, .2,.2) such 
that T = ( TI , T2 , T3 ) = (0,0, 0), in a historically heterogeneous response resulting in the 
experimental response profile 1t1 = (lrll,lrI2,lr13) =(.6,.5,.4) with li1 =.5. 
14 
The second scenario is an example of ARH, table lb. Group II contends that 
there is no historical precedent for the usage of drug A on colon cancer, but hypothesize 
a predictive difference based on a combination of two biomarkers resulting in three 
clinically relevant subgroups, both biomarkers present, both absent and one present. The 
response profile for the standard treatment is homogeneous, 1fo = (.3, .3,.3) with 11 = 0, 
and it is the inequality of the treatment effect that is the source of the heterogeneity, 
() = (.3, .2,.1) such that 'T = (.25, .15, .05) , leading to an experimental response profile of 
1f[ = (.6, .5,.4) with 7[[ =.5. 
The third example is an example of GRH, table Ie. Group III suspects that there 
is both a prognostic effect based on cancer staging and a predictive effect based on the 
biomarkers. There is both a heterogeneous historical treatment effect, 11 = (.33, .03, 0) 
such that 1fo = (.51, .21, .18), and heterogeneous treatment effect with 
'T = (0, .20, .03) such that () = (.09, .29, .12). The experimental response profile is then 
1f[ =(.6,.5,.4) with 7[[ =.5. 
The fourth group hypothesizes a more complex interaction between cancer 
stage and biomarker status as a combination of HRH and ARH only affecting a 
subsample of the subgroups, table ld. Historically, the researchers feel evidence only 
provides a two subgroup prognostic difference in the efficacy of the drug, stage I vs. 
Stage II-III with the status of the biomarker only affecting the second group, Stage II-III. 
This results in 1fo = (.35, .275, .275) with 11 = (.075,0, 0). The interaction between 
15 
biomarker status and the second prognostic subgroup leads to T = (0, .15, 0) for an overall 
experimental response profile of 1t] = (.55, .55,.40) with treatment effect profi Ie 
'-( 70 7T 17-) o - . _ ,. _ ),. _) . 
Table 1 Numerical example of three classes of response heterogeneity. 
a:HRH b:ARH 
* J* ~ * J* Ji 7rs '7; 7rs ; T; 7rEi 7rs 17; 7rs ; Ti 7rEi 
.20 .20 .40 .20 0 .20 .60 .30 0 .30 .05 .25 .30 .60 
.20 .10 .30 .20 0 .20 .50 .30 0 .30 .05 .15 .20 .50 
.20 0 .20 .20 0 .20 .40 .30 0 .30 .05 .05 .10 .40 
c: GRH I d: GRH II 
* J* ~ * 17i J* Ti ~ 7rs 17i 7rSi Ti 7rEi 7rs 7rSi 7rEi 
.18 .33 .51 .09 0 .09 .60 .25 .075 .35 .20 0 .20 .55 
.18 .03 .21 .09 .20 .29 .50 .25 0 .275 .125 .15 .275 .55 
.18 0 .18 .09 .03 .12 .40 .25 0 .275 .125 0 .125 .40 
2.4 Heterogeneity Imbalance 
A second component to heterogeneity, heterogeneity imbalance, is a measure of 
the mean difference between subgroup population proportions or between accrual 
weights. Let w = ( wI' w2"'" Wg ) be the vector of weights for i = 1,2, ... , g subgroups, 
then a measure of the information provided by w is the absolute difference in magnitude 
between the subgroup weights, denoted the heterogeneity imbalance, 
IWi-Wi·1 g =2 





where C, 7 is the combination of g pairwise elements. 
,~ .-
The simplest case is balanced population proportions where I = O. To distinguish 
between population heterogeneity and accrual heterogeneity, fa will be used to denote 
accrual heterogeneity. Heterogeneity imbalance will be used as a method to classify the 
range of heterogeneity and as a component to increase the sample size in the latter 
sections of the paper. 
2.5 Clinical trial errors 
Trial parameters are constructed such that the trial errors are maximized with 
respect to the target errors. Under a frequentist design, the target errors are the Type I 
and Type II errors. The errors are composed of four joint probabilities which specify the 
complete trial outcome space (Lee and Zelen 2000). The joint probabilities quantify the 
probability of the trial outcome, acceptance or rejection of the alternative hypothesis, and 
the population truth, the population response rate is greater than or equal to the target 
response rate or less than the target response rate, 
P(R-) = p( Reject HI ,lZ' < lZ'1); 
P(R+) = p( Reject Hi' lZ' ~ lZ'1 ); 
subject to, I I P( ij) = 1. 
i=(A.R) j=(+.-) 
P( A-) = P ( Accept Hi' lZ' < lZ'j ) ; 
P(A+) = P (Accept Hi' lZ' ~ lZ'j ), 
The first joint probability, P(R-) , is the probability of rejecting the alternative 
hypothesis and the null hypothesis is true in the population. While the fourth joint 
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(12) 
probability, P(A+), is the probability of accepting the alternative hypothesis and the null 
hypothesis is not true in the population. The frequentist errors, are constructed, 
Type I = a = p( Accept HI l;r < lrl ) = P(A-) - P(A-)+P(R-) 
Tvpe II = fJ = P(Reject H I lr 2 lr ) = P(R+) 
~ I I P(R+)+P(A+) 
2.6 Trial errors under the subgroup assumption 
Under a subgroup assumption the construction of the errors is not as 
straightforward as in section 2.5 due to the averaging constraints which allow for a 
multiplicity of weight*response profiles, 
g 
W1t = ( WI lrl ' W 2 , lr2 ' ... , W g lrg ) ; L Wilri = lr , 
i=1 
that sum to a single fixed response rate (Barnes and Rai 2010). The usual assumption, in 
homogeneous Phase II trials, is that only a single response exists and given this response 
and a set of critical values and sample sizes, the errors can be constructed. Under a 
subgroup model, the assumption of the single response still exists, through the mean 
response rate, but there exist two levels of additional variation which can result in the 
single mean response rate. The first level is the weight profile. The second level is the 
actual response profile. Multiple different combinations of weights and response profiles 
can lead to a single response rate. 
Under a specific single fixed response rate and within each weight profile, there 





constraint, TCT = L WiTCTi ; T = 0, I . Table 2 displays multiple possible weight*response 
i~1 
profiles that satisfy equation (3), a weighted average, given a 40:60 scheme and ito = .30. 
Table 2: Multiple weight*response profiles satisfying response rate constraint 
WI w2 TCOI TC02 it= L WiTCi 
.40 .60 .73 .01 .30 
.40 .60 .55 .13 .30 
.40 .60 .31 .29 .30 
.40 .60 .24 .34 .30 
To illustrate the added complexity the problem when heterogeneity exists under a 
mean of the weight*response profile, we will examine how to construct an error rate 
through simulation. Error rates are means, e.g. expected values. For example, under a 
binary model, given a response rate, sample size and a critical value, (TC,n,r) 
respectively, we can compute the type I error as follows through simulation 
h 
L I ( x > r I TC = TCo ) 
Ct= E[x> rITC=TC
o
] =...!..:i-::.!..-I _____ _ 
b 
(15) 
where b is the number of simulations, x is the sum of responses with critical value rand 
indicator variable I (.) . 
If one chooses to partition the above simulation into, S sub-simulations or partitions 
denoted [s], the errors could still be constructed by taking the mean of the sub-simulation 
errors since each subgroup simulation is exchangeable, 
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(16) 
which is equivalent to 
h 




a = E [ x > r I lZ" = lZ"o] = --'----------'- (17) 
s 
Under latent heterogeneity, the form of the type I error in (17) is not correct since 
the partition is not exchangeable. In (16), the composition of the conditioning is exactly 
the same across all sub simulations, e.g. exchangeability, a homogeneous condition. 
Under a heterogeneity subgroup assumption, and say for explanation, only four 
possible weight*response profiles existed to satisfy the averaging constraint, the 
conditioning is not exchangeable. Each weight*response profile results in a separate set 
of errors, a heterogeneous conditioning. For example, given the first line of table 2, 
(.73,.0 l) , a type I and type II error exist. Separate Type I and Type II errors also exist 
for each of the remaining weight*response profiles. 
Under a subgroup assumption, S is not exchangeable. We assume that the 
weights are fixed. Each partition S = s results in a unique partitioning of the complete 
space for a fixed weight profile. Under this assumption, (16) becomes 
(18) 
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where the complete space S is composed of all possible partitions satisfying the 
weighted average constraint 
(19) 
Taking the expectation, under non-exchangeable subgroups, will result in an overall 
double expectation that is generally bounded by the target errors. This is not appropriate 
under a clinical trial context. 
The trial design must guarantee that the error is bounded by the target error for 
every non-exchangeable subgroup; the double expectation only guaranteed this on 
average. A clinical trial will always be conducted with a specific response profile, 
whether known or not known, and the trial design errors must be guaranteed to be 
bounded by the target error. 
A more appropriate estimate for the errors under heterogeneity where non-
exchangeable subgroups exist 
.\ 
LJ (fJ[iJ > fJ) /J = ....:..i=--'-I ___ _ (20) a = ..-'-i=--:..I ___ _ 
s s 
where a(i) and fJCi) are the type I and type II errors for each partition, e.g. a specific 
weight*response profile satisfying the weighted averaging constraint. The trial errors are 
then the mean number of times a partition error crosses the target error boundary over all 
possible partitions of the complete fixed weight profile space. If a trial is designed to 
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control the errors in (20), then the trial is guaranteed to control the errors at a specific 




LITERATURE REVIEW: EXISTING METHODS FOR HETEROGENEITY 
Five methods have been developed to handle response heterogeneity in single arm 
Phase II clinical trials. The methods cover both frequentist and Bayesian designs. A 
commonality between most methods is the reliance on a known composition structure to 
the subgroups; not including the Beta-binomial methodology. 
3.1 Unconditional and Conditional Stratified Methods 
The methods proposed by London and Chang, unconditional stratified and 
conditional stratified methods, account for subgroups with a binary response, similar to a 
stratified log-rank test for time-to-event data, under a k-stage design (London and Chang 
2005). 
Given a known covariate with g subgroups for stages j = 1,2, ... , m, ... , k , 
let Rm = I ;~l I;=l Rij be the sum of responses across all subgroups up to an intermediate 
stage m where Rij is the sum of responses for the ith subgroup in the jth stage. The total 
sample size across k stages is denoted N = I~~l I;~l Nij. Furthermore, let the sampling 
weights be proportional to the true population profile, then the general form of the test 
statistic for the unconditional stratified method is 
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"m ("g (R -NICo )) L.. j=1 L..i=1 I} lj I 
Km = -;============== "m ("X N1[o (1-1[0 )) 
L.. J=1 L..I=I lj I I 
(21) 
Sample size computation and critical value determination are completed using an 
iterative simulation algorithm with set percentages of type I and type II errors spent in 
each stage similar in development to the Simon design; see (London and Chang 2005). A 
set of stopping boundaries, (( 11' UI ), (l2' U2 ), ... , (Uk)) , where (ll' U1 ) are the futility and 
efficacy boundaries for stage 1 respectively, are constructed to maintain the target type I 
and type II errors for the trial. This is in contrast to the Simon design where only a 
futility boundary exists. The final result is a sample size and test statistic(s) based on the 
estimates for the true population proportions of each subgroup, the sampling weights. 
Since the true population proportions of the subgroups are not usually known in 
practice, a second form the test statistic was proposed, the conditional stratified method. 
The sample size and outcome of the trial are conditioned on the sampling weights, as 
opposed to the true proportions, of each subgroup. Conditioning equation (21) on 
( Nil J = (!!:!lJ, ... , (Nim J = (nim J ' it can be seen that both "m "g n1[. and the N N L..,=IL..I=1 I) 01 
1 ~ m nm 
denominator of (21) are constants given (nil"'" nim , 1[Oi ). The sum of responses up to 
the immediate stage m is asymptotically equivalent to Km and the rejection region of the 
null hypothesis can be expressed as Rm > rm where rm is the critical value of the test 
statistic for the mth stage. The general form of the test statistic for the mth stage of the 
conditional method is 
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The final test statistic for k stages is the sum of independent random variables, 
In contrast to the unconditional method, many solutions exist to (22) by varying 
each of the subgroup sampling weights through ( ~: J ~ ( :: J under the type I and type 
II error constraints. This allows for a wide range of possible accrual scenarios and results 
in a similar output as the initial output, before making the selection of the minimax and 
optimal solutions, of the Simon designs (Simon 1989). 
3.2 Beta-Binomial Method 
The third method, the beta-binomial distribution has been previously proposed as 
a model that can account for heterogeneity in binary outcome models (Makuch, Stephens 
et al. 1989; Yamamoto and Yanagimoto 1994; Hendriks, Teerenstra et al. 2005; Hunt and 
Rai 2005; Dragalin and Fedorov 2006; Young-Xu and Chan 2008). For simplicity, we 
assume only one stage. To allow for an increase in variation of the response over the 
binomial, a subgroup composition is assumed for the responses where response rates are 
allowed to vary, Jri - beta( a 0 ,bo) . Then Ri] I Jri ' has a binomial distribution. The 
marginal of Rj is a beta-binomial with probability function, 
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(23) 
The mean and variance are 
(24) 
a 
where TC = 0 The parameter p is the correlation between the response rates and 
ao +bo 
quantifies the excess heterogeneity in the response profile above the binomial 
distribution. If P = 0 , then the variance of RI degenerates into the binomial variance. 
After estimation of the parameters (ao' bo) , the sample size and test statistics can be 
calculated based on the type of difference to be detected (Hendriks, Teerenstra et al. 
2005; Chow, Shao et al. 2007). It should be noted that the estimation of the parameters 
does not require subgroup source knowledge, prognostic or predictive, about the 
heterogeneity; only the estimated amount of variation. 
3.3 Bayesian Hierarchical Methods 
To implement Phase II designs from the frequentist perspective, a fixed response 
rate, whether a single rate or response profile, is specified. Alternatively, a Bayesian 
design incorporates a level of uncertainty in the fixed rate by assuming that the response 
is random through the use of prior and hyper-prior distributions. A primary design 
principle this approach is that the parameters of the response are not independent, but 
correlated similar to the beta-binomial distribution (Lee 2009). One such model is the 
26 
Bayesian hierarchical model (BHM) which assumes a hyper-parameter distribution for 
the priors, If! , to model the heterogeneity and correlation of the parameters. The joint 
distribution of all parameters is constructed by combining the data likelihood, prior and 
hyper-prior distributions, 
f (R. 1t. 'I' ) = 1 (R 1 1tl p( 1t 1'1' 1 p( 'I' 1 = J n~, 1 (R~~"., ~ !'(:\"~ IjIl} h~ (25) 1 likelihooJ 
with trial decision making using the posterior distribution, 
f f (R, 1t, 'I' )dlf! 
P( 1t I R) = --=-=-----f feR, 1t, 'I')dBdlf! 
Due to the intractability and high dimension of the posterior, Monte Carlo Markov Chain 
MCMC methods are used to compute the posterior probabilities for each stage of the trial 
(Gilks, Richardson et al. 1996). 
The fourth heterogeneity method, Bayesian normal-binomial hierarchical model 
used in Thall et. ai., is based on the logit model (Collet 2003; Hunt and Rai 2003) and is 





) with 1fI=(I1,a2 ), 11- N(V[,cp[2) and a 2 - N(v2 ,cp/). (27) 
The subgroups are assumed to be exchangeable implying no a priori prognostic 
difference in response rates. The heterogeneity is assumed to be predictive. 
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One advantage in using the Bayesian approach is the existence of within subgroup 
stopping boundaries allowing for partial subgroup efficacy/futility as opposed to a global 
boundary, e.g. Simon or London and Chang methods. As such, a set of identical within 
subgroup stopping boundaries, due the exchangeability of the subgroups, are constructed 
for each stage of the trial. Once all the patients in subgroup i are evaluated, futility and 
efficacy stopping boundaries are applied for this subgroup, 
and 
P(tru > trOi I data) ~ Lt, 
using the data from all subgroups to determine if a particular subgroup portion of the trial 
should be stopped or continue accrual until the next decision point using an appropriately 
small value for I and a large value for u. The values for the boundaries are usually 
chosen to give good operating characteristics when compared to a frequentist design. 
Each subgroup has an identical stopping boundary similar to running multiple 
simultaneous trials with the conditioning allowing the sharing of information across 
subgroups and minimization of resources by using the data from all subgroups to 




3.4 Bayesian ANCOV A Method 
The fifth method, Bayesian normal-binomial regression model or BANCOV A 
model, was proposed by Wathen and Thall (2008). To compare the model with the 
earlier heterogeneity notation of (6), the model was reparameterized. The model, 
fa gil ( reT g ((J) ) = ~ + I ;=1 { 77i + r/ (T = I)} I (G = g) , 
is constructed with 771 = 0 for interpretational convenience. It should be noted that the 
ranges of the parameters are not consistent between the heterogeneity model (6) and the 
model (30) which the models mean response rate on the logit scale. Model (30) has no 
assumption on the structure of the variance as in model (27), where 
iid 
~ = 10 gil ( re;) ~ N (f-L, (Y2) is assumed, modeling the mean response as opposed to both 
the mean and variance of the response. 
The prognostic effect of subgroup g compared with the baseline subgroup, e.g. 
subgroup 1, is 'lg and the predictive effect for subgroup g is Tg. To construct the hyper-
parameters for each of the priors, Wathen and Thall developed an algorithm assuming 
small variances for historical priors and large variances for experimental priors by 
equating the moments of a beta distribution to a normal distribution. For the complete 
hyperparameter algorithm and the logic for their assumptions, see (Wathen, Thall et al. 
2008). 
Once the priors have been computed, the posteriors are constructed using MCMC 
methods. Subgroup-specific stopping boundaries are then constructed similar to (28) and 
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(30) 
(29) where the subgroup specific stopping boundaries (I;, uj ) are subgroup dependent on 
the prognostic effect as opposed to the BHM model where the boundaries are identical. 
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CHAPTER 4 
AN ADAPTIVE PHASE II DESIGN TO ACCOMMODATE HETEROGENEITY 
We present a method to account for latent heterogeneity under the Simon design 
context which adapts the second stage sample size and critical value of a Simon design 
based on the outcome of the first stage under the presence of a heterogeneity statistic. 
The adaptive design denoted the 2-stage heterogeneity adaptive design (2HA) preserves 
the operating characteristics of the Simon trial under no heterogeneity, e.g. no change to 
the design, and preserves the first stage operating characteristics, moderate probability of 
early termination. For simplicity and due to the relatively small sample sizes in Phase II 
trials, detecting only two groups is attempted. 
The basic algorithm is as follows, compute the Simon design parameters given a 
weighted average response rate, which asymptotically e.g. n --7 00 , mirrors the population 
response and conduct the first stage of the trial. After the first stage and the first stage 
criterion was met, x> 'i ' determine if subgroups exists through a classification algorithm. 
If the trial fails to meet the first stage critical value, the trial has failed. The etiology of 
the failure is unknown; either the trial design failed due to latent heterogeneity or the 
probability that the response meets or exceeds the clinically relevant response is minimal. 
Under this scenario, no change to the second stage will result in a successful trial and will 
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not be considered as relevant to the design at this point. The design focuses only on trials 
that have met the first stage criterion. 
Once the subgroups are identified, the subgroups are tested for the presence of 
heterogeneity. If no heterogeneity is detected, enroll the remaining patients per the 
Simon sample size parameters and complete the trial using the Simon critical value. If 
heterogeneity is detected using a liberal test, the overall sample size will be increased, 
with the additional sample size for the first stage included in the new second stage sample 
size, using an empirically derived inflation factor. A new critical value will be 
constructed given the new second stage sample size and that the trial has succeeded into 
the second stage. 
The Beta-Binomial posterior predictive distribution is used as the model 
distribution to determine new parameters under heterogeneity. Enroll the additional 
patients and test the global hypothesis with the new critical value. This new design will 
control the errors bounded at the target errors given knowledge on the average response, 
!"Co and !"C], the number subgroups expected, g = 2. 
4.1 Subgroup identification 
This design relies on the ability of a classifier to find the true subgroups in the 
sample. Multiple methods exist for finding subgroups in supervised and unsupervised 
manners. A supervised classifier is one in which the true identity of the object being 
classified is known. For example, supervised classification can be conducted on age or 
gender. In both instances, the true state is known. Unsupervised classifiers are ones in 
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which the true state is not known and is estimated through patterns in the data. An 
example may be a set of unknown biomarkers. The true state of the unknown biomarkers 
is generally not known. Patients are grouped into subgroups based on the expression 
patterns of these biomarkers. 
The study of supervised classifiers is a broad subject with many classifiers that 
fall under this category. Some examples are recursive algorithms such as random forests, 
machine learning algorithms such as support vector machines or statistical classifiers 
such as linear discriminate analysis or principal component analysis. 
The most popular method for unsupervised learning is clustering algorithms. 
Clustering is the assignment of samples into subsets based on a distance or dissimilarity 
measure which measures the distance between samples based on the data (Datta 2006). 
Multiple types of clustering exist such as agglomerative methods, and k-means. See 
Romesburg for an exhaustive summary of the multiple methods that exist (Romesburg 
2004). 
For the purposes of this paper, the classifier is assumed to have 100% accuracy. 
This is to remove any variation that might be caused by the actual classifier. In the case 
of unsupervised classifiers, there may be a level of error associated with either the 
classification method based on a small sample size as is the case in Phase II trial first 
stages or error associated with the measurement platform such us the case with high 
through-put micro array platforms. 
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The classifiers for these reasons will be assumed to be built using supervised 
variables, say age and gender. In this case, the classifier will always have 100% 
classification accuracy. The utilization of non- perfect classifiers in the algorithm is a 
subject for future work. 
4.2 Testing for heterogeneity 
Multiple methods exist for testing the assumption of heterogeneity or 
overdispersion in binomial data under a grouped data assumption. The preferred method 
is to test for lack of fit of the data to the binomial model with parameter Jr (Collet 2003). 
We focus on global goodness-of-fit methods where the test statistic evaluates the 
unspecific hypothesis, model fits versus model does not fit. 




respectively (Kuss 2002). As the number of groups increases, g ---7 00 , the two test 
statistics should be approximately equal, X 2 "'" D. Under the context of this problem, 
two groups and only one sample of each group, there is lack of data, known as sparcity, 
which results in X 2 -:j:. D. The sparcity is due to the fact that only one example of the 
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data exists during a single trial, e.g. n = 1. It has been shown that for n ::; 5 , the Pearson 
test is too conservative and the Deviance test is erratically anticonservative (Kuss 2002). 
This undermines the use of either statistic as a robust method of determining 
heterogeneity. 
A third method is to use a modified Pearson test statistic where the Pearson 
statistic family is generalized by adding an additive constant to X2 first described by 
Farrington, 
(33) 
The standardized test statistic is then compared to a standard normal distribution 
(Farrington 1996). This method has been shown to be more stable than either the 
deviance or standard Pearson statistics under sparcity (Kuss 2002). 
Due to the sparcity of the data, heterogeneity is determined using a liberal p-value 
threshold, p::; .30. The motivation for using a liberal p-value threshold is that it is 
advantageous to err on the heterogeneity side. If heterogeneity truly does exist and the 
test determines no heterogeneity, the Simon trial parameters are not a good fit to the data. 
The reverse, the test determines heterogeneity when heterogeneity does not exist, will 
result in the use of the Beta-Binomial which will still provide an adequate fit to the data. 
In simulation, the Farrington test had a power to detect heterogeneity above 
80%. The type I error is inflated, -30%, which is allowable since the model distribution 
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will still fit and will result in a only modest increase in sample size. This is shown in the 
results section. 
4.3 Variance inflation factor 
To increase the sample size in the second stage to account for the response 
heterogeneity requires estimation of a variance inflation factor (VIP). The standard 
interpretation of the VIP is as an unknown scale parameter which relates the variance of a 
Binomial random variable to the variance of an overdispersed Binomial random variable, 
a Beta-Binomial random variable, section 4.3.1. This interpretation, under a two stage 
trial, will not result in a robust estimate since it relies on estimation of the VIP through a 
Pearson or Pearson type statistic. 
A second interpretation for the VIP is the inflation factor necessary to increase the 
sample size to account for heterogeneity, section 4.3.2. Empirical results are used to 
construct this definition. This method will result in a robust method that leads to a 
sample size that will control the trial errors at the target errors. 
4.3.1 Estimation of theoretical VIF 
Given the following model, 
for i = 1,2, ... ,g , we can compute the variance of the observed responses, Xi' 
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(34) 
v (Xi) = E[ n/ri (1- Jri ) ] + V (niJr i) 
= ni ( E [ Jri ] - E [ Jri 
2
]) + ni
2rpJri ( 1- Jri ) 
= ni ( Jri -rpJri ( 1- Jri ) - Jri 2 ) + ni
2rpJri ( 1- Jri ) 
= niJri ( 1 - Jri ) [ 1 + ( ni - 1) rp ] 
Under the special case Tli = n for all i , 
V ( Xi) = TlJri (1 - Jri ) [ 1 + ( n - 1) rpJ ' 
'------y-----' 
,,2 
such that (52 is denoted the heterogeneity factor and rp is denoted the VIF. Since, 
it follows that 
E [X 2 ] "" g [ 1 + ( Tl -1) rpJ = g (52, 
~ 6"2 -1 
rp=-
n-] 
Equation (36) provides the standard interpretation of the VIP and estimation through 
equations (37) and (38). Under the special case of a two stage trial, where only a single 
sample is used, the stage one results, the estimation of the VIF through (38) will not be 
robust due to sparcity. 
The use of the Farrington X 2 to replace the standard X 2 was allowed in section 
4.2 for the heterogeneity test statistic since it is advantageous to err on the side of 
heterogeneity. The only error which must be controlled absolutely is the Type II error; 






estimation of the VIF. The VIF is directly correlated with the resulting sample size of the 
trial. In tum, the sample size is directly correlated with the trial errors. Allowing for 
inadequate control of the errors in the estimation of the VIF will result in adequate 
control of the trial errors. 
4.3.2 Estimation of empirical VIF 
A second logical approach to estimate the VIF is through the trial conduct. The 
increase in variation can be attributed to two components not present under a 
homogeneous population, the weight profile and the response profile. Under a 
homogeneous population, the response profile is a single response. The second 
interpretation of the VIF is as the minimum amount necessary to increase the sample size 
to account for heterogeneity. 
Given the first stage results and the presence of heterogeneity, an estimate for the 
heterogeneity imbalance, j can be estimated through (11). The absolute magnitude of 
difference in the response profile can be estimated 
where itli = ~ is the estimate of the response in the ith subgroup with response Xi and 
nli 
2 2 
sample size n1i such that LXi = X and L n1i = n1 . Equation (11) provides information on 
i=l i=l 
the weight profile while equation (39) provides information on the response profile 
beyond the information provided by a fixed homogeneous response rate. For simplicity, 
the number of subgroups is 2. 
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(39) 
A natural estimate for the VIP for a single trial is the product of the estimate of 
the heterogeneity imbalance and the response rate imbalance, 
A new sample size to account for heterogeneity can be constructed 
where n is the original Simon total sample size. When the heterogeneity imbalance is 
non-existent, j = O. Small differences in the response profile lead to a small VIP. As 
either the difference in weight profile diverges or the difference in the response profile 
diverges, the sample size will increase. 
4.4 Model Distribution 
Once heterogeneity has been detected through subgroup identification, the trial no 
longer adheres to the assumption of a Binomial distribution. As such, the Binomial trial 
parameters and model are no longer valid. Two factors will determine the new model 
distribution, the structure of the trial and the structure of the data. 
4.4.1 Predictive posterior Beta-Binomial 
The structure of the trial is a two-stage process and this process should be 
inherently modeled in the model distribution for parameter construction. The data is 
structured such that 






where X is the sum of responses in the first stage of the data. This two-stage process and 
the extra-binomial variation due to (42) and (43) can be explicitly modeled using the 
posterior predictive Beta-Binomial distribution. 
The posterior predictive distribution (PP) quantifies the probability of a future 
observation of the data, y, out of m samples given some data has already been observed, 
x, out of n samples, 
In the case of a two-stage trial, the PP distribution quantifies the distribution of the stage 
two outcome given the stage one outcome. In addition, by treating the parameter JZ" as 
random, as opposed to a fixed as in the binomial distribution, the variance of X is larger 
than a strictly single parameter binomial model for X . 
For completeness, the composition of the Beta-binomial is repeated, removing 
subgroup notation for simplicity, 
p(JZ") - Beta(ao,bo); p(xlJZ") - Bin(n,JZ"); 







where Beta ( x; a, b) = I ( qJ ),,-1 (1- qJ) d qJ. The first distribution in (45) is the prior 
distribution of the response parameter Jr. The second distribution is the data likelihood 
which satisfies the data structure in (42). Combining the data prior with the data 
likelihood results in the posterior distribution p (Jr I x). Heuristically, one can interpret 
the posterior distribution, p (Jr I x) , as an assumption distribution, p (Jr) , updated with 
actual data from the trial, p ( x I Jr) . 
Then, it can be easily seen that the PP distribution is Beta-binomial through the 
conjugateness of the Beta distribution and Binomial distribution, 
p(ylx)= fp(y,Jrlx)dJr 
= fp(YIJr)p(Jrlx)dJr 
"'" Bin(n-ni'Jr)Beta(Jr;ao +x,bo +nl-x) 
= Beta (ao,bo) -lBeta( Jr;ao + y,bo + (11- nl ) - y) 
where Beta ( au' bo) = r ( ao) r (bl)) / r ( ao + bo). The extra-binomial variation or 
heterogeneity is modeled through the data prior (See (24». 
4.4.2 Prior specification 
The standard practice in prior specification is to specify a non-informative prior. 
A non-informative prior will minimize the impact of a subsequently misspecified prior on 
the overall posterior distribution (Lee 2009). Non-informative priors are priors with large 
variance. The standard method to parameterize a non-informative Beta prior is to base 




example, basing a beta prior with Jt = .30 and n = 1 will result in the parameterization of 
ao = .30 and bo = .70 since 
(47) 
As the sample size that the prior is based upon increases, the variance of the random 
response rate shrinks towards zero as seen in table 4. 
Table 3 Mean and variance for different prior specifications by sample size 
n (ao,bo) 1r V(1r) 
1 (.3,.7) .30 .105 
10 (3,7) .30 .033 
100 (30,70) .30 <.01 
The prior for our model will be based on the null response given a sample size of 
n = 1 which will result in the parameterization given in (47). 
4.2.3 Beta-Binomial predictive posterior error construction 
The structure of the errors in section 2.5 can be used to develop the errors for trial 
design using the Beta-Binomial PP distribution (Barnes and Rai 2010). The joint 
probability of outcome and truth in a k-stage trial is composed of (k+ 1) subspaces, k stage 
outcomes and the population truth. For a two stage design, the joint probabilities are 
specified as follows, 
P ( outcome, truth) = P ( outcome stage 1, outcome stage 2, truth). (48) 
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The joint probabilities are specified using the conditional probabilities and marginal 
probabilities of the (k+ 1) components through Bayes theorem. 
P(A-) = P( Jr < Jrl ,Accept HI) 
= P ( Jr < Jrl' X > 'I ' x + Y > r) 
= P ( Jr < Jr1 I x > 'I, x + Y > r) P ( x + y > r I x > 'I ) P ( x > 'I ) (49) 
III n-fl t 
= I I p(Jr<Jrlly=j,x=i)P(y=jlx=i)P(x=i) 
i=r,+1 j=r+l-i 
The joint probabilities that include an accept outcome are intuitive. This is not the case 
for the joint probabilities which include a reject outcome. 
Under a two stage design, if the first stage criterion is not met, then the trial stops 
without proceeding stage two. To specify the joint probabilities under rejection, it is 
necessary to include the conditional probability of the second stage criterion not being 
met given the first stage criterion is not met; a situation which is impossible in actual trial 
conduct. This specification is not intuitive, but necessary to assure that the total outcome 
space is complete. 
The probability of rejecting the alternative hypothesis and the null hypothesis is 
true is the sum of the product of the conditional probability that the null hypothesis is true 
given the first stage criteria is not met, the conditional probability that the second stage 
criteria is not met given that the first stage criteria is not met, and the marginal 
probability that the first stage criteria is not met and the product of the conditional 
probability that the null hypothesis is true given the trial is successful, the conditional 
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probability that the second stage criteria was met given the first stage criteria was met, 
and the marginal probability that the first stage criteria was met, 
P( R-) = P(ff < ffl ,Reject HI) 
= P ( ff < ffl ' X S Ij , x + Y S r) + P ( ff < ffl ' X > Ij x + y S r) 
= P ( ff < ffl I x S Ij ) P ( x + Y sri x S Ij ) P ( x S Ij ) + 
P ( ff < ffl I x + y > r, x > Ij ) P ( x + y > r I x > Ij ) P ( x > Ij ) 
'i r-i 
= I I P ( ff < ffl I y = j, x = i) P ( y = j I x = i) P ( x = i) + 
i=O j=O 
n1 r-i I I P ( ff < ffl I y = j, x = i) P ( y = j I x = i) P ( x = i). 
i=r,+1 j=O 
The remaining two joint probabilities are similarly found replacing ff < ffl with 
ff?: ffl . Once all four joint probabilities are constructed, the errors in section 2.5 (13) can 
be constructed. The chosen set of parameters is the set of parameters satisfying the error 
constraints and resulting in the optimal solution as with Simon's design. 
4.5 Two stage Adaptive Heterogeneity trial algorithm 
Combining the theory in the previous sections, an algorithm for the 2HA design is 
constructed which determines the trial outcome. For simplicity, the number of subgroups 
to be detected is two. The algorithm is as follows: 
1. Compute Simon parameters given a null response rate, ffo' treatment effect, 0, 
and target errors, Ct, fJ resulting in parameters Ij, nl ,r, n 
2. Conduct first stage of trial using Simon parameters resulting in the number of 
successes, observed value x 
44 
(50) 
3. Determine if a classifier exists to partition the first stage sample into two groups. 
Test for heterogeneity using the Farrington test, 
If a classifier does not exist, proceed to step 6. 
4. Calculate a new maximum sample size, n *, given the observed heterogeneity 
imbalance and observed absolute difference in response profile, n* = n ( 1 + i Iffll) . 
5. Calculate a new critical value, r* I (X = 'i,n *), using the Beta-Binomial PP 
distribution given that the first stage criterion was met for n * under the target 
errors. 
6. Conduct the second stage under the appropriate sample size. If no heterogeneity 
exists (r, n) ; if heterogeneity exits, (r*, n *) resulting in observed value y 
7. Compare x + y to r under no heterogeneity and to r * under heterogeneity. If 
x + y > r or x + Y > r * , then the trial is estimated to be a success. 
4.6 Estimation of response rate 
It has been shown that under multiple stage designs, e.g. sequential tests, the 
maximum likelihood estimator (MLE) is generally biased (Li and Li 2000; lung and Kim 
2004). Since only extreme cases are observed in a 2-stage Phase II trial, e.g. crossing a 
futility boundary in stage 1 or crossing an efficacy boundary in stage 2, an optional 
sampling effect is introduced biasing the MLE (Whitehead 1986). The optional sampling 
effect causes the variance of the estimate to increase thus increasing the bias. The bias is 
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most pronounced in trials with only a futility boundary in stage 1, as compared to both a 
futility and efficacy boundaries, which is the case with both the Simon and 2HA designs. 
lung and Kim have shown that in a two stage trial the statistic (M, S) , where 
iV/ denotes the stage the trial terminates, M = {I, 2} , and S denotes the total number of 
responses accumulated up to and including stage M , is a complete and sufficient statistic 
for 1l", the response rate of the trial. 
Then, since itj = Xj / nj is an unbiased estimator of Jr I M = 1 and the complete and 
sufficient statistic (M, S) , the uniformly minimum variance unbiased estimator 
(UMVUE) of 1l"can be constructed by the Rao-Blackwell theorem (Blackwell 1947), 
(51) 
which will not ,by definition, suffer from the bias of the MLE in a sequential test. The 
UMVUE for 1l", given a two stage trial is then 
(52) 
where (nj' n - nj ) are the first and second stage sample sizes and 'l is the first stage 
futility boundary (lung and Kim 2004). 
As an example, say that the following responses were observed at the end of the 
second stage of a trial (m, s) = (2,7) with trial parameters ('l, nj , r, n) = (3,13,12,33). The 
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support space, e.g. the summation space, is constructed for the UMVUE, 
(~ + 1) u ( s - n + nl ) = (3 + 1) u (7 - 30) = 4 and s (j (nl -1) = 7 (j (14 -1) = 7 resulting in 
7 [13-1J[ 30 J 
A I( ) ~ i-I 7-i 
JrUIHVUE m = 2, s = 7 = 7 (J( 1 = .322 I ~I 30. 
i=..j 1 S-l 
In contrast, the MLE is it MLE = ~ = .212 which is heavily downward biased. 
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Using these results and the composition of the source of the heterogeneity, 
estimable and identifiable subgroups, a general form of the UMVUE can be constructed. 
Given the sum of responses in stage one and stage two follows a Binomial distribution, 
( Xi + ~) I Jri - Bin ( ni , Jri ) for each subgroup, the UMVUE of the response rate Jr is the 
weighted sum of the UMVUEs for each individual subgroup, 
where nl is the sample size for subgroup g in the first stage, n, is the total sample size g 8 
for subgroup g and /jg = wg/j is the weighted first stage critical value for the gth 
subgroup. A weak. assumption of independence is assumed and the assumption that the 





EFFECTS OF HETEROGENEITY ON PHASE II TRIALS: RESULTS 
5.1 Effects of heterogeneity on Simon trial designs 
For simplicity, the number of subgroups in the simulations was chosen to 
be g = 2. Given a combination of weight and response profile, the type I and type II 
errors were computed using Bl = 10,000 Monte Carlo iterations. Due to the multiplicity 
of combinations of response/population profiles with a common mean response and to 
allow 7[Ti where 7[Ti > 7[Ti' for i =f. i' to be uniformly distributed across the g subgroups, 
(B2 I g = 2) = 40,000 Monte Carlo iterations were conducted; for example, 
(B2 I g = 2) = 4 and 7[s = .25 using a simple average can result in 
(
, )_f(.1,.9,.30,.20) (.1,.9,.40,.IO)} 
W1,H'2,7[OI,7[02 -l( ) l.I,.9,.20,.30 (.1,.9,.10,.40) 
(55) 
5.1.1 Simulation parameters 
A sample of population proportion profiles were chosen to cover a heterogeneity 
imbalance of j = (0,.98) for the two subgroup simulations and was simulated as follows: 
1. Under HRH or ARH, given the population profile for a imbalance I , the first 
(g -1) historical response rates, 7[Oi' were randomly generated from a uniform 
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distribution, lCOI ' lC02 " .. ,lCOI g-I) ~ U ( 0, ltO + 8*) where (lts' 8*) are specified, for 
example (lts' 8* ) = (.25, .15). The parameters for the uniform distribution are 
problem specific and are to subject to the constraints 0::; lCOi ::; I for all i. The 
gth null response rate was generated to satisfy the averaging method. The 
alternative response rate was constructed in a similar fashion for the HRH and 
ARH classes. Under GRH, the odds ratio of each subgroup was constrained to 
equal the odds ratio for the Simon design such that, 
solving for lCli given lCOi ' Then, 8,. = lCli -lCOi • 
2. If accrual is allowed to diverge from the population profile, an accrual profile is 
constructed for each subgroup to replace the population profile, 
first (g -1) subgroups at (Wi ± da) . 
3. Given a population or accrual profile and a response profile, simulate multinomial 
random variables nll , n21 , ••• , n~ I with fixed sample size nl and cell 
probabilities 1fT = ( lCTi ' lCn ' ... , lCT Ii ) • 
4. For values of ( Nil' N 21"" ,N g 1) = ( n ll , n21"'" ng 1) , simulate binomial random 
variables XTi with sample size nil and response rate lCri · Then xT = I~=l XTi is 
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compared to the critical value fj derived from the Simon trial design using the 
target mean response rates and nominal errors. If xT ~ fj , then the trial is stopped 
for futility. 
5. If xT > fj , repeat steps (3-4) for the second stage, 112 to determine y ; otherwise 
hI = O. Compare xT + h to the critical value r from the Simon trial design. If 
XT + YT > r , then the null response rate is rejected. 
6. Repeat steps (2-5) for B1 = 10 000 simulations and T = (0,1). Then, 
(I:~I I (xo + Yo > r) / B) I 1[ = 1[0 is the type I error of the test and 
(I:~I I (XI + YI :::;; r) / B) I 1[ = 1[1 is the type II error of the test. 
7. Repeat steps (1-6) for B2 combinations of response and population profiles. 
Construct the actual type I and type II errors using equation (20). 
5.1.2 Results 
The first simulation compared the effect of varying levels of heterogeneity 
imbalance using simple averages for a 2 subgroup trial (Barnes and Rai 2010). The data 
was simulated using R.9.2 (Team 2005). The target type I and type II errors are 
(a, 13) = (.10,.20). Table 5 displays the errors with corresponding 95% quantile intervals 
for each class of heterogeneity. Under all three classes of heterogeneity and a 
heterogeneity imbalance of I :::;; .20, the actual mean errors approximate the target errors. 
When the imbalance increases, I > .20 under HRH and GRH, the actual mean errors 
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exceed the target errors with increasing divergence as the imbalance increases. Under 
ARH, the type I mean error approximates the target error with the type II following a 
similar, but less extreme divergence pattern as HRH and GRH. As the imbalance 
increases, the ranges of error estimates increase with the exception of the ARH type I 
estimates which maintain a constant quantile interval irrespective of the imbalance. The 
effect of heterogeneity is most pronounced on the type I error range under HRH and more 
pronounced on the actual type II error range under GRH. Under an unknown response 
profile for 2 subgroups, the mean probability that trial is moderately to extremely 
oversized is 22%, 1& - al ~ .04, and the mean probability that the trial is underpowered is 
42%, 1;1 - pi ~ .04 . 
To further identify the effect of heterogeneity, tables 6 and 7 display the 
probability distributions for the oversizing or underpowering of the trial. Under HRH 
and GRH, as the heterogeneity imbalance increases, the mass of the error estimate 
distributions location shift increasing farther to the left resulting in larger divergences 
from the nominal errors. This results in strong negative effects of heterogeneity on the 
trial operating characteristics. For example, for I = .20 under HRH, the majority of 
oversized trials are in the range of (.10, .12] , a small divergence from the nominal errors. 
When 1=.40 and 1= .80, the majority of oversized trials are in the ranges of (.2,.3] and 
(.4,1] respectively, substantial divergences from the target error and of high concern to 
the trial conduct; a similar pattern in seen with the actual type II errors. The exception is 
the oversized trials under ARH. Irrespective of the heterogeneity imbalance, the majority 
of oversized trials are only slightly oversized in the range of (.10, .12]. This would imply 
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that even though the trials are oversized, the effect of the heterogeneity is minimal on the 
type I error. 
Table 4: Size and power for each class of heterogeneity by heterogeneity imbalance with 
corresponding 95% quantile and Monte Carlo intervals for a 2 subgroup example 
Actual 95% Actual 95% 
Class I Error I QI Error II QI 
HRH .02 .10 (.08, .11) .20 (.18, .22) 
.20 .11 (.04, .20) .21 (.11, .32) 
.40 .13 (.01, .34) .22 (.06, .46) 
.60 .16 (0, .50) .25 (.03, .61) 
.80 .20 (0, .65) .28 (.02, .76) 
.98 .23 (0, .76) .31 (.01, .86) 
ARH .02 .10 (.09, .11) .20 (.18, .22) 
.20 .10 (.09, .11) .20 (.14, .28) 
.40 .10 (.09, .11) .21 (.09, .37) 
.60 .10 (.09, .11) .22 (.06, .47) 
.80 .10 (.09, .11) .23 (.04, .58) 
.98 .10 (.09, .11) .24 (.03, .67) 
GRH .02 .10 (.08, .11) .23 (.19, .30) 
.20 .11 (.04, .20) .24 (.14, .46) 
.40 .13 (.01, .34) .26 (.07, .66) 
.60 .16 (0, .50) .30 (.03, .83) 
.80 .20 (0, .65) .33 (.01, .94) 
.98 .23 (0, .76) .36 (0, .98) 
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Table 5 Distribution of actual type I error for each class of heterogeneity and 
heterogeneity imbalance for a 2 subgroup example. 
Distribution of Actual Type I Error 
Class I (aMe - .12] (.12-.14] (.14-.18] (.18-.2] (.2-.3] (.3-.4] >.4 
HRH .02 .31 .01 0 0 0 0 0 
.20 .09 .10 .17 .08 .04 0 0 
.40 .05 .05 .09 .04 .17 .09 0 
.60 .03 .03 .06 .03 .12 .12 .12 
.80 .02 .03 .04 .02 .09 .07 .22 
.98 .01 .03 .04 .01 .08 .06 .27 
ARH .02 .26 0 0 0 0 0 0 
.20 .26 0 0 0 0 0 0 
.40 .26 0 0 0 0 0 0 
.60 .26 0 0 0 0 0 0 
.80 .26 0 0 0 0 0 0 
.98 .26 0 0 0 0 0 0 
GRH .02 .31 .01 0 0 0 0 0 
.20 .09 .10 .17 .08 .03 0 0 
.40 .05 .05 .09 .04 .17 .09 0 
.60 .03 .03 .06 .03 .12 .10 .12 
.80 .02 .03 .04 .02 .09 .08 .22 
.98 .01 .03 .04 .01 .08 .06 .27 
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Table 6 Distribution of actual type II error for each class of heterogeneity and 
heterogeneity imbalance for a 2 subgroup example 
Distribution of Actual Type II Error 
Class I (fJMC -.22] (.22 - .24] (.24-.28] (.28 - .3] (.3-.4] (.4 - .5] >.5 
HRH .02 .36 .02 0 0 0 0 0 
.20 .08 .09 .16 .07 .08 0 0 
.40 .04 .05 .08 .04 .17 .12 .12 
.60 .03 .03 .06 .03 .11 .10 .25 
.80 .03 .03 .04 .02 .08 .08 .31 
.98 .01 .02 .03 .01 .07 .07 .35 
ARH .02 .37 .01 0 0 0 0 0 
.20 .18 .15 .12 .01 .01 0 0 
.40 .10 .09 .14 .05 .lO .01 .lO 
.60 .06 .07 .12 .05 .13 .05 .06 
.80 .04 .06 .08 .05 .13 .08 .13 
.98 .03 .05 .07 .02 .13 .09 .18 
GRH .02 .29 .21 .19 .06 .03 0 0 
.20 .06 .07 .07 .05 .14 .10 .lO 
.40 .04 .02 .07 .01 .11 .08 .24 
.60 .03 .02 .03 .03 .07 .07 .32 
.80 .02 .03 .01 .02 .08 .05 .35 
.98 .01 .02 .01 .01 .07 .03 .38 
The second scenario is the weighted average, table 7. Under HRH and ARH, the 
actual mean errors maintain the target errors with the quantile confidence intervals only 
slightly larger than the Monte Carlo error bounds. The mass of the actual error 
distributions are in the range of (.10, .12] and (.20, .22] respectively, a divergence between 
target and actual errors implying that some trials do not meet the error targets. Under 
weighted averages, the effect of heterogeneity is minimal, but not absent, on the 
operating characteristics of the Simon trial. 
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Table 7 Errors for each class of heterogeneity by heterogeneity imbalance with 
corresponding 95% quantile for a 2 subgroup example using weighted averaging. 
Actual 95% Actual 95% 
Class I Error I QI Error II QI 
HRH .02 .10 (.09, .11) .20 (.18, .22) 
.20 .10 (.09, .11) .20 (.18, .22) 
.40 .10 (.08, .12) .20 (.18,.22) 
.60 .10 (.08, .12) .20 (.18, .22) 
.80 .10 (.08, .12) .20 (.18, .22) 
.98 .10 (.09, .12) .20 (.18, .22) 
ARH .02 .10 (.09, .11) .20 (.18, .22) 
.20 .10 (.09, .11) .20 (.18, .22) 
.40 .10 (.09, .11) .20 (.18, .22) 
.60 .10 (.09, .11) .20 (.18, .22) 
.80 .10 (.09,.11) .20 (.18,.22) 
.98 .10 (.09. 11) .20 (.18, .22) 
GRH .02 .10 (.09, .12) .20 (.18, .24) 
.20 .10 (.09, .12) .20 (.18, .24) 
.40 .10 (.08, .12) .21 (.18, .24) 
.60 .10 (.08, .12) .22 (.18, .25) 
.80 .10 (.08, .12) .22 (.18, .25) 
.98 .10 (.09, .12) .23 (.18, .24) 
To allow for the uncertainty in either the true proportions or the accrual, two 
levels of error were introduced during patient accrual, da = .05. The accrual 
heterogeneity imbalance was allowed to vary between 0 and 5% of the population 
heterogeneity imbalance. The accrual difference can be attributable to accrual divergence 
or error in proportion estimation. Table 8 shows the results for g = 2 subgroups with an 
accrual divergence parameter of 5 %. The actual mean errors approximated the target 
errors in almost every case with the exception being under GRH actual type II errors. 
The reason for this divergence is unknown at this time. The distributions of the errors are 
more dispersed than the weighted average method due to the variation in accrual which 
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leads to more specific combinations of a weight and response profile being underpowered 
or oversized.. The strength the errors is increased when comparing the error estimate 
distributions between weighted averages and weighted averages with accrual divergence. 
Table 8 Simon Optimal design with s=2 subgroups population using weighted average 
with accrual differences, aa = .05. 
Actual 95% Actual 95% 
aa 1 Error I CI Error II CI 
HRH .10 .02 .10 (.07, .14) .20 (.16, .24) 
.20 .10 (.07, .13) .20 (.16, .24) 
.40 .10 (.08, .14) .20 (.16, .24) 
.60 .10 (.07, .12) .20 (.16, .24) 
.80 .10 (.08, .13) .20 (.16, .24) 
ARH .10 .02 .10 (.09, .11) .20 (.17, .23) 
.20 .10 (.09, .11) .20 (.17,.23) 
.40 .10 (.09, .11) .20 (.17, .23) 
.60 .10 (.09, .11) .20 (.17, .23) 
.80 .10 (.09, .11) .20 (.17,.23) 
GRH .10 .02 .10 (.07, .14) .20 (.16, .26) 
.20 .10 (.07, .13) .21 (.17, .26) 
.40 .10 (.07, .12) .22 (.17,.38) 
.60 .10 (.07, .12) .22 (.17,.29) 
.80 .10 (.08, .13) .23 (.17, .34) 
5.2 Effects of heterogeneity on Adaptive trial design 
5.2.1 Simulation parameters 
The data for the 2HA simulation was simulated in a similar manner as with the 
Simon simulation in section 5.1.1. Only two groups under GRH were simulated with the 
weighted average constraint. Under latent heterogeneity, GRH is the most appropriate 
class of heterogeneity. It is also assumed that if a response rate was hypothesized, that 
the rate was hypothesized from data that follows the population as a whole. For example, 
if a trial response rate of .30 is hypothesized, then the population in general follows a 
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mean response of .30. No subgroups are known prior to trial conduct, though this does 
not occlude the existence of said subgroup, and a Treatment x Marker interaction is not 
known. For each weight scheme of the weighting profiles, 10,000 simulations were 
conducted. The actual errors, the percentage not meeting the target errors, are reported. 
5.2.2 Simulation Algorithm 
The data was simulated using a Linux cluster by parallelizing the simulation using 
R.9.2 (Team 2005). The data and trial conduct is simulated as follows 
1. Given a null response rate and alternative response rate with a specified weighting 
scheme, 1Co' 1CI ' ( WI' w2 ) , and target errors, (a, [3) construct the Simon trial 
parameters and a null and alternative response profile by weighted averages 
satisfying the odds ratio criterion. 
2. Given a weight profile and an alternative response profile, simulate multinomial 
random variables nil' n21 with fixed sample size nl and cell probabilities 
3. For values of (Nil' N 21 ) = (nil' n21 ) , simulate binomial random variables Xi with 
sample size nil and response rate 1Cli • Then X = I~=I Xli is compared to the 
critical value 1) derived from the Simon trial design. If X ~ 1) , then the trial is 
stopped for futility. 
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4. If X> fj then determine if heterogeneity is present using the Farrington X 2 statistic 
and a liberal p-value, p;:::: .30. 
5. Compute the heterogeneity imbalance and absolute magnitude in difference in 
responses. Then constmct a new sample size, n * using (41). 
6. Repeat steps 2-5 for B=50,000 iterations. 
7. Given the unique possible new sample sizes in the 50,000 iterations, constmct 
new critical values, r * , given fj out of n1 responses in the first stage and for 
each of the new sample sizes using the predictive posterior Beta-Binomial 
distribution. 
8. If p;:::: .30 , then n2 = n * -n1 and r = r * ; otherwise, n2 = n - n1 and r = r . 
9. Repeat steps (2-3) for the second stage, n2 to determine y ; otherwise y = O. The 
h 
Z)(x+y:s;r) 
power of the test, 1 - fJ is constmcted such that 1- fJ = -"i==.!.l ____ _ 
b 
10. Repeat steps 2-6 for the null response rate. Given the new sample size, the critical 
values determined using the alternative response are used. 
11. If p;:::: .30 , then n2 = n * -n1 and r = r * ; otherwise, n2 = n - n1 and r = r . 
h 
Z)(x+y>r) 
12. The size of the test or ais constmcted such that a=....:..i=....:..l ____ _ 
b 
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13. Repeat steps 1-12 for 10,000 iterations of different response profiles that satisfy 
the weighted average given the weight profile. The trial errors given a weight 
profile are then constructed using (20) where s = 10,000. 
14. Repeat all steps for each weight profile, 
w = {( .1,.9), (.2,.8), (.3,.7) ,(.4,.6), (.5,.5)} . 
This algorithm results in the estimates of the trial operating characteristics given a 
specific weight profile and any possible response profile satisfying the weighted average 
constraint. 
5.2.3 Results 
Under latent heterogeneity, the appropriate form of heterogeneity is generalized 
response heterogeneity. Under GRH, no information is known a priori on the source of 
the heterogeneity. A two subgroup trial was simulated under GRH. Table 9 shows the 
results given 10,000 simulations of weight*response profiles satisfying the weighted 
average response rate constraint for the following parameters 
1[0 = .30; 1[1 = .45; a = .10; f3 = .20 . 
The errors reported are the percentage of times the individual weight*response 
profile errors crossed the target error boundaries in the inappropriate direction, 
ab > a and Pb > f3 where the weight*response type I error for the bth simulation is ab . 
a 2HA and as denote the type I error for the Adaptive and Simon designs. As with the 
59 
Simon simulations, the expected value of the size and power are very close to the targets, 
but it is the range that is more clinically important or as a proxy, the percentage above the 
target error bounds. 
Table 9 Simulated error estimates for various weight profiles with target errors of 
(a,p) = (.1,.2) and (Jro,JZJ = (.30,.45). 
WI w2 I a2HA fJ2HA as Ps 
0.1 0.9 .8 0 0.18 0.22 0.40 
0.2 0.8 .6 0 0.17 0.l5 0.40 
0.3 0.7 .4 0 0.14 0.08 0.30 
0.4 0.6 .2 0 0.05 0.04 0.28 
0.5 0.5 0 0 0 0 0 
The adaptive design maintains the target type I error under all levels of 
heterogeneity, e.g. weight profiles. The error increases as the heterogeneity imbalance 
increases, but is below the target type II error. This is not the case with the Simon 
design. From the simulations in section 5.1, the divergence from the target is marginal, 
within, for example, fJ ± .05, but under the conduct of these type of trials, any divergence 
from the target is the wrong direction is clinically substantial. 
The Simon design does meet the target errors with an equal weight profile. As the 
heterogeneity imbalance increases, the percentage of trials under a specific weight profile 
that exceed the target error bounds increases. In the case of extreme weighting of the 
subgroups, 1=.8,40% of the trials will not have a minimum of 80% power with 22% of 
the trials oversized which can result in a successful Phase II trials but be the cause of a 
failed Phase III trial. 
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A second consideration of Phase II trials is the expected sample size of the trial. 
Given a weight profile, summary statistics can be computed for the expected sample size 
under heterogeneity for the 2HA design which relate the mean, standard deviation and 
confidence intervals for the total sample size and expected sample size EN following (5) 
where the mean or confidence interval is substituted for n, 
EN(Ho) = ~ +(1- PET)(n -~) (56) 
Given (Jro, Jr1 ) = (.30, .45) and (a,,8) = (.10,.20) , the Simon trial design results in 
the following parameters and operating characteristics, 
(~,n, PET, EN) = (20,55,.6070,41.24) under the optimal design. Under the Adaptive 
design, the PET remains the same. Given 10,000 simulations of weight*response 
profiles for each weight profile, the sample size summary statistics are listed in table 11. 
Table 10 Sample sizes under the 2HA design 
I n[sd] Range EN(Ho I I) 95% CI for EN 
.8 70 [7] (55, 105) 50.37 (41.62,59.11) 
.6 63 [ 6] (55, 105) 45.98 (38.78, 53.18) 
.4 59 [4] (55,102) 43.94 (38.82,49.05) 
.2 58 [3] (55,98) 42.83 (39.50,46.18) 
0 57 [3] (55,100) 42.59 (39.49,45.69) 
Under the extreme case of heterogeneity imbalance, 1=.8, the 2HA design 
results in an average increase of 27% of the Simon sample size with a corresponding 49% 
increase in the expected sample size to control the trial errors at the target errors. As the 
heterogeneity imbalance decreases, the expected sample size decreases as does the mean 
sample size. In the case of no heterogeneity imbalance, the 2HA design only increases 
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the sample size by 2 with an increase in the expected sample size of -1. This provides a 
justification for allowing the type I error to be inflated for the heterogeneity test. If 
heterogeneity is detected where none is truly present, the trial will only lead to a minimal 
increase in sample size. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Summary and conclusions 
The primary purpose of a Phase II trial is to estimate if a treatment has a clinically 
meaningful effect on a group of patients for further more targeted testing. Generally, ex 
vivo evidence exists which provides evidence that the treatment does have efficacy on 
either tissue samples or cell lines. The purpose of the Phase II trial is to demonstrate this 
efficacy on a small subset of the affected patient population. If the Phase II trial is 
successful, then either more targeted Phase II trials are conducted or the treatment moves 
on to Phase III testing. Phase III testing provides the definitive answer as to the efficacy 
of a treatment. 
Phase II trials have some unique properties not seen in the earlier or later phases 
of clinical trials. The trials are a single arm with no control arm. Though there is a move 
towards Phase II trials with a randomized design with control and treatment arms, the 
majority of Phase II trials are still single arm. The sample size in these trials is small, 
from only 10 patients up to 120 patients. As such, Phase II trials only estimate a 
response, and the larger Phase Ills are used to define the response. As the name suggests, 
the type of trial is early in the drug development so historical information on the efficacy 
of the treatment or the patient population may be lacking. 
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All trials, Phase I-IV, rely on some homogeneity of the population to draw 
inferences. In a Phase III trial or a randomized Phase II trial, the control and treatment 
arms are expected to be similar, e.g. homogeneous in response. This is not always 
possible in a Phase II trial. With only one arm, the homogeneity does not rest between 
two samples, e.g. two trial arms, but rests on the homogeneity of the response in a single 
population. The single population being tested, through the response rate, must be 
homogeneous. Phase Ills do not need this assumption; only that homogeneity exists 
between samples. For example, a Phase III or randomized Phase II can have multiple 
subgroups in the trial, each with a unique response rate. As long as the distribution of the 
subgroups is the same across the two arms, the homogeneity assumption is met. In a 
Phase II trial, no comparison can be made, so subgroups cannot exist. All patients must 
come from the same population with the same response. This assumption can be lacking 
in actual trial practice and poses a substantial hurdle to accurate inferences from said 
trials. 
The most common Phase II trial design is the Simon Phase II designs as 
described in section 2.1. These designs rely on a homogeneity assumption in the 
response in order for the trial data to fit the model distribution of the trial parameters, the 
Binomial distribution. In practice, subgroups may exist causing a divergence in the trial 
data from the Binomial distribution. A large number of Phase II trials fail. It is 
paramount to determine why these trials have such a high failure rate. In examining the 
problem, multiple failure modes can be suggested, 1) the trial fails due to inaccurate 
estimation of the true response rate, 2) the trial fails due to difference in the patient 
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population cells and ex vivo cell lines, 3) the trial fails due to the use of a homogeneous 
trial design when heterogeneity exists. This paper has focused on third failure mode. 
Response heterogeneity can be constructed from a set of subgroups in the 
population with subgroups having either unique response rates or unique etiologies of 
their response rates. This paper provided a model for heterogeneity to quantify the 
effects of heterogeneity on trial designs. The model was applied to the popular Simon 
design and the Simon design was shown to have inflated errors beyond the target errors 
rates across all three classes of heterogeneity. This is a standard practice in clinical trials, 
subgroups are known to exist but for simplicity and to minimize patient resources, a 
single trial is conducted using an averaged response with the Simon designs. Intuitively, 
the inflation of error would be expected when a simple average is used to combine a set 
of subgroup response rates into a homogeneous response rate. Under simple averaging, 
there is no weighting to the average, but in fact, the population may have a specific 
weighting profile. Hence, the simple average response rate may substantially diverge 
from the true weighted population response rate. 
To correct for this, weighted averages were also applied to the Simon designs. 
In theory, the weighted average would correspond to the weighted average of the 
population and correspond to a homogeneous response rate mathematically. This would 
hold true except for one issue. The response is a weighted sum of binomials, but the 
weighted sum of binomials is not binomial. Hence, the use of a binomial model 
distribution may not be appropriate. The simulation results confirm this fact. While the 
expected value of the errors across simulations, given a weight profile, usually did 
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maintain the target errors, the range of actual errors crossed the target error bounds. 
Specific weight*response profiles would exceed the target error bounds. In trial conduct, 
any divergence is substantial since the trial is designed to never exceed the target error 
bounds. 
From a clinical interpretation using the expected value under heterogeneity is not 
valid as a measure of the trials errors. Trial designs must maintain a target error for every 
specific weight*response profile or within an allowable error level. The Simon designs 
do not have this operating characteristic under heterogeneity. Hence, even under 
weighted averages, the Simon design will not maintain the target errors. This provides 
solid evidence that the Simon trial design may be a source of the high failure rates of 
Phase II trials. Under homogeneity, the Simon design is the most efficient design, but the 
design was not constructed to handle heterogeneity. 
In order to develop a new design to handle heterogeneity, multiple current 
methods were evaluated. All of the methods that have been developed in the past few 
years suffer from a limiting factor, the composition of the subgroups must be known in 
advance. It can be argued that if subgroups are known to exist, the most conservative 
path is to conduct separate trials for each subgroup. This is a second common practice, in 
opposition to averaging, conduct multiple trials. This can lead to a substantial increase in 
trial resources which may be a motivating factor for using an averaged response. 
In practice, subgroups are not generally known at such an eady stage of a 
treatment's efficacy exploration. Failed Phase lIs provide solid evidence for future Phase 
II's with the same or similar treatment. As more Phase II's are conducted a better image 
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of the treatments efficacy is refined. This approach uses the accumulation of trials to 
accumulate and refine knowledge on the existence and composition of subgroups, but is 
costly when evaluating patient and financial resources. Ethically, if a more optimal 
solution to the allocation of patient resources exists, then this optimal method should be 
utilized. When no information is available at the beginning of trial conduct, the type of 
heterogeneity is known as latent heterogeneity and corresponds to the generalized 
response heterogeneity class of the heterogeneity model. This would correlate to the first 
conduct of a Phase II trial. We suggest a more optimal method than conducting multiple 
Phase II trials to refine efficacy estimates. 
We have developed a new Phase II design that can handle latent response 
heterogeneity with a modest increase in the sample size. The new design works by 
incorporating the trial structure, a two stage process, and the data structure, subgroups, 
into the model distribution of the trial parameters, the Beta-Binomial posterior predictive 
distribution. The predictive posterior form is chosen to account for the two stage process 
of the trial. The trial starts as a standard Simon design with Simon design parameters. 
After the first stage has concluded, the trial data, a single grouped sample, is tested for 
the existence of subgroups using an unsupervised classification algorithm. Then a 
heterogeneity test is computed. If heterogeneity is detected, the trial's overall sample 
size is increased by an empirically determined variance inflation factor. 
The variation inflation factor is the empirical estimate of the product of the 
magnitude of the response profile and the magnitude of the weight profile from the first 
stage conduct. This method to increase the sample size seems very intuitive. The 
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response heterogeneity can be decomposed into two sources which differ in 
heterogeneous responses as compared to a homogeneous response, weight and response 
profiles versus no weights and a single fixed response rate. Multiple other methods were 
tried, but no method was able to consistently maintain the errors across all possible 
weight profiles. The trial uses the posterior predictive Beta-Binomial distribution to 
construct a new critical value by an exact method to determining the trial errors. 
This new design, the 2-stage heterogeneity adaptive design, is shown to never 
exceed the target trial errors. Even with an extreme heterogeneity imbalance, the target 
trial errors are maintained. Under small or no heterogeneity imbalance or a small 
difference in the response magnitude, there is only a marginal increase in the total or 
expected sample size. This fact gives credence to the earlier use of a very liberal 
heterogeneity test. With only a single grouped sample, no single heterogeneity test is 
reliably going to result in robust inferences or always control the type I error, the 
probability of determining heterogeneity when one exists. The chosen heterogeneity test, 
the Farrington test, does maintain an acceptable level of power, >80% which is of 
primary concern. If one does not detect heterogeneity when it truly exists, then the 
Simon design is not appropriate. The scalable sample size based on the variance inflation 
factor results in only minimal increases in sample size when heterogeneity is detected, 
but truly not existent. 
A limiting factor of this design is the determination of subgroups. A full 
exposition of how to determine subgroups from an unsupervised approach is beyond the 
scope of this paper, but the limitations imposed by this issue are understood. A second 
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limiting factor is the stopping of the trial to determine the existence of subgroups. Many 
designs have been developed which maintain the operating characteristics of the Simon 
design but allow for continuous patient accrual with no between stage stopping. Many 
clinicians may feel that waiting a few weeks between stages is too long, but in the end, 
this extra time may result in a saved trial. As such, the determination of the classifier and 
the time is takes to determine the classifier are limitations to this design. 
In conclusion, the 2-stage heterogeneity adaptive design maintains the target 
errors of a binary 2-stage single arm trial. The trial design preserves the desirable 
operating characteristic of the Simon design, moderate probability of early termination, 
without a substantial increase in trial resources. The increase in trial resources is 
determined by the first stage results. If subgroups are detected and the imbalance in these 
subgroups either in weights or response rates is high, then the increase in the overall 
sample size compared to the Simon trial will be substantial. In no way, it is claimed to be 
the minimum necessary increase in sample size, but through simulation was shown to 
always be adequate. This method works under the full range of possible heterogeneity 
which will at times result in larger than necessary sample sizes. 
6.2 Direction for future work 
This design presents multiple areas of limitation that need to be addressed. The 
primary limitation is the detection of subgroups. More work is needed to indentifying an 
unsupervised classification algorithm that can work under the small sample sizes in the 
first stage of a Phase II clinical trial. An unsupervised algorithm presents a very practical 
case since the source of heterogeneity in many diseases is determined to be genomic. If a 
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classifier is used that does not have perfect classification, then an additional source of 
variation is introduced into the problem. In this case the VIP becomes the product of 
both the weight and response profiles and the classification accuracy. Less accurate 
classifiers will result in an increase in the sample size. Secondly, a better test for 
heterogeneity that preserves the type I error would also be an optimal improvement. 
The detection of only two groups is adequate for trials where the sample size is 
relatively small, but in larger Phase II trials, the detection of more than two groups should 
be possible. Understanding what the limitations are for a higher detection number and 
robust tests are necessary. The use of the Beta-Binomial posterior predictive distribution 
provides a necessary correction factor for heterogeneity in the second stage of the trial. 
Work needs to be conducted to determine if it would be more optimal to not start as a 
Simon Design, but conduct the entire trial using the posterior predictive distribution. 
A final improvement would be to include local hypothesis tests. The most 
desirable attribute of the Bayesian ANOV A and hierarchical methods is the sharing of 
information across subgroups and allowing for subgroup specific stopping or acceptance. 
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